Teva Pharmaceutical Industries (TEVA) Net Cash Flow (2016 - 2025)
Historic Net Cash Flow for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $1.4 billion.
- Teva Pharmaceutical Industries' Net Cash Flow rose 122330.1% to $1.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $235.0 million, marking a year-over-year decrease of 524.19%. This contributed to the annual value of $235.0 million for FY2025, which is 524.19% down from last year.
- Teva Pharmaceutical Industries' Net Cash Flow amounted to $1.4 billion in Q4 2025, which was up 122330.1% from $51.0 million recorded in Q3 2025.
- Teva Pharmaceutical Industries' Net Cash Flow's 5-year high stood at $1.4 billion during Q4 2025, with a 5-year trough of -$1.6 billion in Q1 2025.
- In the last 5 years, Teva Pharmaceutical Industries' Net Cash Flow had a median value of $108.5 million in 2022 and averaged $90.7 million.
- Per our database at Business Quant, Teva Pharmaceutical Industries' Net Cash Flow skyrocketed by 168611.11% in 2023 and then tumbled by 115801.53% in 2025.
- Over the past 5 years, Teva Pharmaceutical Industries' Net Cash Flow (Quarter) stood at $201.0 million in 2021, then surged by 113.93% to $430.0 million in 2022, then surged by 111.4% to $909.0 million in 2023, then tumbled by 88.67% to $103.0 million in 2024, then surged by 1223.3% to $1.4 billion in 2025.
- Its Net Cash Flow stands at $1.4 billion for Q4 2025, versus $51.0 million for Q3 2025 and $469.0 million for Q2 2025.